Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Traditional Chinese medicine raw material as well as preparation and use thereof

A technology of pharmaceutical preparations and raw materials, which is applied in the field of drug raw materials and preparations of cyclovirboxicin D, and can solve problems such as lack of in-depth research

Active Publication Date: 2015-04-01
西藏易明西雅医药科技股份有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The document "Pharmacological and Toxicological Research Survey of Cycloviral Boxuxine D" (Nanjing University of Traditional Chinese Medicine Master's Degree Dissertation), pages 52-53 discloses the research on the toxicology of Cycloviral Boxuxine D. It has certain nephrotoxicity, but this document does not conduct in-depth research on the material basis of cyclovirboxicin D, that is, whether cyclovirboxuxin D is nephrotoxic in raw materials or impurities are nephrotoxic, or What impurities are nephrotoxic, and no in-depth research has been conducted

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Traditional Chinese medicine raw material as well as preparation and use thereof
  • Traditional Chinese medicine raw material as well as preparation and use thereof
  • Traditional Chinese medicine raw material as well as preparation and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] A pharmaceutical raw material, wherein the content of cyclovirbuxine D is 90.0%, the content of cycloprotopoxine C is 9.9%, and the rest is 0.1%.

[0109] The above raw materials are prepared into aqueous injections, transfusions, powder injections, tablets, capsules and the like.

[0110] Wherein the aqueous injection is composed of: 1 g of Cycloviral Buxusin D raw material, 1000 ml of water for injection, an appropriate amount of tris-hydrochloric acid buffer solution (adjusting the pH value to 5.0); or 1 g of Cycloviral Buxusin D raw material, 1000 ml of water for injection, Appropriate amount of citric acid (adjust pH=5.0).

[0111] The composition of the powder injection: 1 g of cyclovir buxus D raw material, 1000 ml of water for injection, 40 g of mannitol, an appropriate amount of tris-hydrochloric acid buffer solution (adjust the pH value to 5.0); or 1 g of cyclovir buxuxin D raw material, manna Alcohol 50g, water for injection 1000ml, appropriate amount of cit...

Embodiment 2

[0113] A pharmaceutical raw material, wherein the content of cyclovirbuxine D is 93.5%, the content of cycloprotopoxine C is 6.3%, and the rest is 0.2%.

[0114] The above raw materials are prepared into aqueous injections, transfusions, powder injections, tablets, capsules and the like.

[0115] Wherein the water injection is composed of: 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, an appropriate amount of tris-hydrochloric acid buffer solution (adjusting the pH value to 5.5); or 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, An appropriate amount of citric acid (adjust pH=5.5).

[0116]The composition of the powder injection: 2 g of cyclovir buxus D raw material, 2000 ml of water for injection, 50 g of mannitol, an appropriate amount of tris-hydrochloric acid buffer solution (adjust the pH value to 5.5); or 2 g of cyclovir buxuxin D raw material, manna Alcohol 50g, water for injection 2000ml, appropriate amount of citri...

Embodiment 3

[0118] A pharmaceutical raw material, wherein the content of cyclovirbuxine D is 96.2%, the content of cycloprotopoxine C is 3.7%, and the rest is 0.1%.

[0119] The above raw materials are prepared into aqueous injections, transfusions, powder injections, tablets, capsules and the like.

[0120] Wherein the water injection is composed of: 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, an appropriate amount of tris-hydrochloric acid buffer solution (adjusting the pH value to 5.5); or 2 g of cyclovir buxicine D raw material, 2000 ml of water for injection, An appropriate amount of citric acid (adjust pH=5.5).

[0121] The composition of the powder injection: 2 g of cyclovir buxus D raw material, 2000 ml of water for injection, 50 g of mannitol, an appropriate amount of tris-hydrochloric acid buffer solution (adjust the pH value to 5.5); or 2 g of cyclovir buxuxin D raw material, manna Alcohol 50g, water for injection 2000ml, appropriate amount of citr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of traditional Chinese medicines and discloses a traditional Chinese medicine raw material as well as a preparation and a use thereof, wherein the pharmaceutical raw material comprises cyclovirobuxine D and cycloprotobuxamine C. Studies find that the content of the cycloprotobuxamine C in the cyclovirobuxine D raw material is within a certain range, and the kidney toxicity of the raw material is significantly reduced; and pharmacodynamic tests prove that the cyclovirobuxine D pharmaceutical raw material disclosed by the invention has great effects of treating angina, coronary heart disease, arrhythmia and the like.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a drug raw material, preparation and application of Cyclovir buxicine D. Background technique [0002] Huangyangning preparation is a preparation prepared from the Buxus family plant-Buxus microphylla as the raw material. It is the first new drug for the treatment of cardiovascular and cerebrovascular diseases in my country. Among them, Huangyangning tablet has been included in the 2000, 2005, and 2010 editions of the Chinese Pharmacopoeia. The above-mentioned drugs belong to traditional Chinese medicine, which plays an important role in the treatment of diseases in clinical application, but traditional Chinese medicine is mostly used as compound medicinal materials or compound extracts, with complex components, unknown non-quantitative components occupy a considerable proportion, and there are many impurities , The curative effect substances are n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/57A61P9/10A61P9/06
Inventor 曹捷高帆周战尚磊
Owner 西藏易明西雅医药科技股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com